Dr. Yuesheng (Jason) Li is a Full Member, a Senior Investigator, a VP for R&D of iGECE and a Molecular Systems Biologist who primarily provides consulting service to our clients in the field of genomics, biological database & data integration, biological data mining & knowledge discovery. His research interest is focused on environmental toxicology and Safety of Nano-materials as well as individualized health solution seeking an effective and efficient therapeutic strategy particularly at a basis of innovative biotechnology. Dr. Li was trained as a molecular and cellular biologist as well as a clinician with research experience in nutriceuticals and pharmaceuticals. He has conducted many independent projects targeting liver or spinal cord ischemia/reperfusion injuries, bladder/breast cancers, infectious bowel diseases, Parkinson’s/Alzheimer’s diseases at the University of Virginia since 2001. His over 25-year research experience covers cell culture, cell proliferation, stem cell, transgenic mouse, cytokine profiling, gene cloning & characterization, data mining for drug targets, drug testing & validating, pharmacokinetic profiling, animal modeling, animal behavioral analyses, herbs screening, statistical analyses , and clinical trial. He was appointed as a WHO liaison for women lactation program as a clinician in China. During his entire career, Dr. Li had cloned more than 40 genes from mouse brown adipose tissue and discovered 2 novel genes with application of 1st generation of gene-array and early bioinformatics tools 15 years ago. He has hold two patents and had more than a dozen of peer-reviewed publications. He has improved and/or established more than 5 different animal disease models. Continuously, he has worked with many different species of animals, from mouse, rat, rabbit, cat, dog, and sheep. He was a Senior Scientist at the University of Virginia Center for Global Health, at which he conducted research of infectious pathogens, particularly in drug discovery project of Clostridium Difficile. Dr. Li also coordinates administrative network of iGECE in developing its business opportunity in the interdisciplinary field of energy, environment, nano-material, agriculture, and health science. He is an energetic scientist with creative mind and superior integrity, not only in the best-trained discipline but also in his private Do-It-Yourself life, demonstrating a technology-orientated multi-task ability performing a wide range of detail oriented functions.

Selected Publications and Patents:
  1. Raphael Rodrigues, Renato Oliveira, Yuesheng Li, Snjezana Zaja-Milatovic, Lourrany Costa, Manuel Braga Neto, Glynis Kolling, Aldo Lima, Richard Guerrant, and Cirle Warren. Intestinal epithelial restitution after TcdB challenge and recovery from Clostridium difficile infection in mice with alanyl-glutamine treatment. Journal of Infectious Diseases, in press, 2013.
  2. Cirle A. Warren, Edward J. van Opstal, Mary S. Riggins, Yuesheng Li, John H. Moore, Glynis L. Kolling, Richard L., Guerrant, Paul S. Hoffman. Vancomycin Treatment's Association with Delayed Intestinal Tissue Injury, Clostridial Overgrowth and Recurrence of Clostridium difficile Infection in Mice. Antimicrobial Agents and Chemotherapy, 57, 689, 2013.
  3. Yuesheng Li, Robert A. Figler, Glynis Kolling, Tara C. Bracken, Jayson Rieger, Ralph W. Stevenson, Joel Linden, Richard L. Guerrant and Cirle A. Warren. Adenosine A2A Receptor Activation Reduces Recurrence and Mortality from Clostridium difficile Infection in Mice following Vancomycin Treatment. BMC Infectious Diseases, 12, 342, 2012.
  4. Cirle A. Warren, Yuesheng Li, Gina M. Calabrese, Rosemayre S. Freire, Snjezana Zaja-Milatovic, Edward van Opstal, Robert A. Figler, Joel Linden and Richard L. Guerrant. Contribution of Adenosine A2B Receptors in Clostridium difficile Intoxication and Infection. Infection & Immunity, 80, 4463, 2012.
  5. Cirle Alcantara Warren, Gina M. Calabrese, Yuesheng Li, Sean W. Pawlowski, Robert A. Figler, Jayson Rieger, Peter B. Ernst, Joel Linden, and Richard L. Guerrant. Effects of adenosine A2A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice. BMC Infectious Diseases, 12, 13, 2012.
  6. Caglar Cekic, Duygu Sag, Yuesheng Li, Dan Theodorescu, Robert M. Strieter, and Joel Linden. Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors. The Journal of Immunology, 188, 198, 2012.
  7. Yuesheng Li, Rod J. Oskouian, Yuan-Ji Day, Jayson M. Rieger, Lei Liu, John A. Kern, and Joel Linden. Novel A2A Adenosine Receptor (A2AAR) Agonist ATL313 Improves Spinal Cord Recovery from Ischemia/Reperfusion Injury in Mice. Neuroscience 141, 2029, 2006.
  8. Yuesheng Li, Rod J. Oskouian, Christopher I. Shaffrey, Jay Jagannathan, Yuan-Ji Day, David B. Bumpass, Rene’ Jack Roy, Stuart S. Berr, John A. Kern, and Joel Linden. Novel and Reproducible Mouse Spinal Cord Ischemia/Reperfusion Injury. Topics in Spinal Cord Injury Rehabilitation 12, 1, 2006.
  9. Yuesheng Li, Rod J. Oskouian, Yuan-Ji Day, John A. Kern, and Joel Linden. Optimization of a Mouse Locomotor Rating System to Evaluate Compression-Induced Spinal Cord Injury: correlation of locomotor and morphological injury indices. Journal of Neurosurgery: Spine 4, 165, 2006.
  10. Yuan-Ji Day, Yuesheng Li, Jayson M. Rieger, Susan I. Ramos, Mark D. Okusa, and Joel Linden. A2A Adenosine Receptors on Bone Marrow-Derived Cells Protect Liver from Ischemia-Reperfusion Injury. Journal of Immunology 174, 5040, 2005.
  11. Yuesheng Li & Joel M. Linden, 2006. Adenosine A2A Antagonists for Spinal Cord Injury. United States Provisional Patent Application Serial No. 60/814,713; June 19, 2006 (Date of Deposit).
  12. John J. Kopchick & Yuesheng Li, 1999. Growth Hormone-Regulatable Brown Adipose Tissue Genes and Proteins, and Uses Thereof (a provisional US patent application filed on May 5, 1999).